AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04109066 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Surgery for breast cancer
Study NCT01091402 — intervention group
Intervention type: PROCEDURE
Intervention: autologous serum skin test, serum IL-18
Study NCT02417532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation using REX
Description: Exercises of wheelchair dependent subjects using REX
Study NCT02561286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRO HIV Risk Reduction Intervention
Description: BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
Study NCT02561286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Intervention
Description: Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals.
Study NCT04894864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Based Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
Study NCT04894864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
Study NCT02949843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02949843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02949843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02949843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted Molecular Therapy
Description: Receive drug targeting secondary mutation
Study NCT02949843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine Kinase Inhibitor
Description: Given PO
Study NCT04450524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
Study NCT04450524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food inhibition training
Description: Training the associations between foods and motor inhibition using a GO-NO-GO computer task.
Study NCT04450524 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A simple GO-NO-GO task
Study NCT00004235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00004235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT03374696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY
Study NCT03374696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Study NCT06730399 — intervention group
Intervention type: DEVICE
Intervention: Computed-assisted-cryotherapy
Description: cryotherapy device
Study NCT02532179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mouse Allergenic Extract
Description: Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
Study NCT00676130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily
Study NCT00676130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily
Study NCT00676130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily
Study NCT02240108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin EIR
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study NCT02240108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study NCT02310555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Study NCT02310555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified gastric bypass.
Study NCT02310555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slevee Gastrectomy
Study NCT03552133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart CO2
Description: A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
Study NCT04274959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ceramic onlay with shoulder preparation design.
Description: ceramic onlay with shoulder preparation design which allowing the largest possible enamel for adhesion ,
Study NCT04274959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ,ceramic onlay with butt joint preparation design
Description: ceramic onlay with butt joint preparation design with cusp reduction to protect teeth from occlusal loads and cuspal fracture
Study NCT00953134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (iron)
Description: 60 mg of ferrous fumarate
Study NCT00953134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: 400 mcg folic acid
Study NCT00953134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: 400 mcg folic acid
Study NCT02591095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Study NCT03360916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 20Mg Tablet
Description: One tablet by mouth every day for 12 weeks.
Study NCT03360916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 80Mg Tablet
Description: One tablet by mouth every day for 12 weeks.
Study NCT03360916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo tablet by mouth every day for 12 weeks.
Study NCT03360916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
Study NCT03360916 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
Study NCT02731937 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GE Healthcare Revolution CT Scanner (CT Scanner)
Description: Raw CT Scan Data
Study NCT02798549 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood draw
Description: blood draw of 150ml, twice
Study NCT02537002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: A single intravenous dose of 3 μg/kg
Study NCT02078947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Continuous Exercise
Study NCT02078947 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Study NCT03314233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DING
Description: Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol.
Study NCT03800264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: PREVENTIVE DOUBLE BLINDED
Study NCT02537002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: A single intravenous dose of 5 μg/kg
Study NCT02423252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage, Relaxation, Guided imagery and music listening.
Description: In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
Study NCT02423252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
Study NCT02537002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single intravenous dose of matched placebo
Study NCT03171480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoket Pill
Description: Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
Study NCT03171480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacy has compounded an identical appearing placebo
Study NCT04660422 — intervention group
Intervention type: OTHER
Intervention: VitalTalk communication skills training
Description: Clinicians will receive VitalTalk intensive communication skills training via highly structured Zoom conference. They will learn skills relevant to discussions about ACP and COVID-19 including delivering serious news, eliciting goals of care, and managing difficult conversations via telehealth platforms.
Study NCT04660422 — intervention group
Intervention type: OTHER
Intervention: ACP Decisions Video Program
Description: All clinicians will also be trained remotely on the ACP Decisions Video Program using the ACP app. Training will instruct clinicians on how to: 1. Introduce the COVID-19 videos to patients and caregivers; 2. Select the appropriate video(s) from the entire suite according to patients' needs; and, 3. Prescribe videos for patients and caregivers using the electronic platform. The suite of ACP videos is designed to address common ACP decisions confronting patients at risk or with COVID-19 and the caregivers.
Study NCT04660422 — intervention group
Intervention type: OTHER
Intervention: Intervention training:
Description: Training will instruct the clinicians on how to: i. more effectively communicate with patients regarding COVID- 19, ii. have ACP conversations with patients, iii. introduce the videos to patients and families, iv. use the videos as an adjunct to ACP counseling by clinicians, v. select the appropriate video(s) from the entire suite as according to patients' needs, and, vi. use the app or electronic platform for prescribing videos to be seen at home (telehealth visits), or to be viewed in clinic with an iPad.
Study NCT04660422 — intervention group
Intervention type: OTHER
Intervention: Medical Record Review
Description: 13,000 (total) patients aged 65 or older for our primary (completed advance care plans) outcome. ACP can include designating a health care proxy, discussion of advance directives, goals-of-care discussions, CPR discussions, palliative care discussions and referrals, as well as hospice. Each of these ACP outcomes will also be compared in secondary analyses using NLP. These data will be obtained from the EHR. All patient participants will only be included for medical record review.
Study NCT01986881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Oral, once daily, for up to approximately 6 years
Study NCT01986881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
Study NCT01986881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
Study NCT01986881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycemic Rescue
Description: Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
Study NCT01986881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycemic Rescue
Description: Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea \[SU\], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.
Study NCT03586752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line program
Description: 18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
Study NCT00536159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medicaid Maternal and Infant Support Services
Description: Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
Study NCT02222480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Study NCT00536159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-CHW team
Description: A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
Study NCT02222480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study NCT02222480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02119143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamines and minerals
Description: given for 24 weeks, after 4 week wash out of all supplements and dietetic products
Study NCT02119143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
Study NCT02163590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2Hz mobilisation
Description: This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
Study NCT02163590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0,5Hz mobilisation
Description: This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
Study NCT02163590 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention that mimics the experimental procedures
Study NCT03265054 — intervention group
Intervention type: BIOLOGICAL
Intervention: Analysis of plasma samples
Description: Measuring microparticles (MPs) in Human Plasma Samples
Study NCT02355067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: These women will participate in the intervention through the online Facebook group.
Study NCT02355067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional In-Person Intervention
Description: These women will participate in the intervention through a traditional weekly meeting of a group in-person.
Study NCT03143114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
Study NCT01257464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg po one dose
Study NCT01257464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill po one dose
Study NCT02564302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUSE Headband
Description: MUSE Headband will help patients with mindfulness.
Study NCT00621608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.